TargetRNA

Great to see the Zimmerman Group's latest in the quest for DM1 therapeutics!

Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1 Multivalent ligands have tremendous potential as therapeutic agents; however, their efficacy is limited by delivery issues, poor cell permeability, and toxicity. We report here a strategy wherein multivalent ligands are designed to be intrinsically cell-penetrating, allowing them to target the expan...